Abstract:Objective To understand clinical distribution and drug resistance characteristics of carbapenem-resis-tant Gram-negative bacillus (CR-GNB), and provide basis for guiding clinical rational use of antimicrobial agents. Methods Clinical isolates of CR-GNB were collected from a hospital between January 2017 and October 2018, statistical analysis was performed by WHONET 5.6 software. Results A total of 9 506 strains of CR-GNB were collected, including 3 879 strains (40.18%) of carbapenem-resistant Acinetobacter baumannii (CRAB), 3 602 strains (37.89%) of carbapenem-resistant Klebsiella pneumoniae (CRKP), 1 322 (13.91%) strains of carbapenem-resis-tant Pseudomonas aeruginosa (CRPA) and 334 strains (3.51%) of carbapenem-resistant Escherichia coli (CREC). CR-GNB mainly distributed in intensive care unit (ICU) (6 340 strains, 66.69%), followed by department of respiratory medicine (751 strains, 7.90%); most strains were isolated from respiratory specimens (6 614 strains, 69.58%), followed by blood specimens (800 strains, 8.42%). Four major CR-GNB were generally resistant to common antimicrobial agents, CRPA was only susceptible to polymyxin B and amikacin, with susceptibility rates of 99.39% and 74.18% respectively; CRAB and CRKP were susceptible to tigecyclin, polymyxin B and minocycline, with susceptibility rates of 60.30%-99.66%; CREC was susceptible to tegacyclin, polymyxin B, amikacin and minocycline, with susceptibility rates of 66.49%-99.13%. Conclusion Antimicrobial resistance of CR-GNB is serious, especially in strains from ICU, clinicians should make more rational anti-infective treatment scheme and strengthen the implementation of infection control measures, reduce the emergence of multidrug-resistant organism and control the spread in hospital.